On Jun 27, 2018 Bank of America Keeps Stock Buy Rating on GW Pharmaceuticals (NASDAQ:GWPH) and $200 Target.

June 27, 2018 - By Loretta Love

Reiterated GW Pharmaceuticals (NASDAQ:GWPH) Rating.

GW Pharmaceuticals (NASDAQ:GWPH) had $200 target price per share given by Bank of America in a note issued to investors and clients on Tuesday, 26 June. Equity analysts’s target price gives a potential upside of 43.53 % from the company’s previous stock close.

GW Pharmaceuticals plc (NASDAQ:GWPH) Ratings Coverage

In total 5 analysts cover GW Pharma (NASDAQ:GWPH). “Buy” rating has 5, “Sell” are 0, while 0 are “Hold”. (NASDAQ:GWPH) has 100% bullish analysts. 10 are the (NASDAQ:GWPH)’s ratings reports on Jun 27, 2018 according to StockzIntelligence Inc. On Tuesday, February 6 the company was maintained by Leerink Swann. On Monday, February 5 the stock of GW Pharmaceuticals plc (NASDAQ:GWPH) has “Buy” rating given by Cantor Fitzgerald. In Tuesday, February 6 report Bank of America maintained the stock with “Buy” rating. On Wednesday, April 18 Cowen & Co maintained the shares of GWPH in report with “Buy” rating. On Tuesday, April 17 Cantor Fitzgerald maintained GW Pharmaceuticals plc (NASDAQ:GWPH) rating. Cantor Fitzgerald has “Buy” rating and $19200 target. The stock rating was maintained by Cantor Fitzgerald with “Buy” on Monday, June 25. On Tuesday, January 23 the rating was maintained by Leerink Swann with “Buy”. On Tuesday, June 26 the company was initiated by Goldman Sachs. On Tuesday, June 26 the company was maintained by Bank of America. On Thursday, December 28 the firm earned “Buy” rating by Leerink Swann.

Ticker’s shares touched $139.34 during the last trading session after 4.89% change.GW Pharmaceuticals plc is uptrending after having risen 49.14% since June 27, 2017. GWPH has 682,486 volume or 54.71% up from normal. GWPH outperformed by 36.57% the S&P500.

Investors wait GW Pharmaceuticals plc (NASDAQ:GWPH)’s quarterly earnings on August, 6., as reported by RTT. The EPS diference is $0.32 or 15.46 % down from last years number. Previous year: $-2.07; Analysts forcast: $-2.39. After $-3.12 EPS report previous quarter, Wall Street now sees -23.40 % EPS growth of GW Pharmaceuticals plc.

GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant.The company has $3.93 billion market cap. The firm operates through three divisions: Commercial, Sativex Research and Development, and Pipeline Research and Development.Last it reported negative earnings. The Company’s lead product is Epidiolex, an oral medicine which is in Phase III clinical development for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.

For more GW Pharmaceuticals plc (NASDAQ:GWPH) news released briefly go to: Benzinga.com, Fool.com, Benzinga.com, Nasdaq.com or Fool.com. The titles are as follows: “Benzinga’s Daily Biotech Pulse: Epidiolex, Roche’s Influenza Drug Gets Priority Review Status, Xeris Jumps On …” released on June 26, 2018, “Why Marijuana Stock GW Pharmaceuticals Gained 21% in May” on June 14, 2018, “420 Investor: Cannabis Drug Approval Creates ‘Logic Issue’ For The US Government” with a publish date: June 26, 2018, “Isodiol International Inc. Applauds the FDA’s Decision to Recognize the Medical Benefits of CBD at Higher …” and the last “Better Marijuana Stock: GW Pharmaceuticals vs. Cara Therapeutics” with publication date: June 10, 2018.

GW Pharmaceuticals plc (NASDAQ:GWPH) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: